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Aims: To determine the pharmacology of ETA- and ETB-mediated β-arrestin recruitment and compare this to
established human pharmacology of these receptors to identify evidence for endothelin receptor biased sig-
nalling and pathway speciﬁc blockade by antagonists.
Main methods: The ability of ET-1, ET-2, ET-3, sarafotoxin 6b and sarafotoxin 6c to activate ETA and ETB-
mediated β-arrestin recruitment was determined in CHO-K1 cells. Afﬁnities were obtained for ETA selective
(BQ123, sitaxentan, ambrisentan), ETB selective (BQ788) and mixed (bosentan) antagonists using ET-1 and
compared to afﬁnities obtained in competition experiments in human heart and by Schild analysis in
human saphenous vein. Agonist dependence of afﬁnities was compared for BQ123 and BQ788 in the ETA
and ETB β-arrestin assays respectively.
Key ﬁndings: For β-arrestin recruitment, order of potency was as expected for the ETA (ET-1≥ET-2>>ET-3)
and ETB (ET-1=ET-2=ET-3) receptors. However, at the ETA receptor sarafotoxin 6b and ET-3 were partial
agonists. Antagonism of ET peptides by selective and mixed antagonists appeared non-competitive. BQ123,
but not BQ788, exhibited agonist-dependent afﬁnities. Bosentan was signiﬁcantly more effective an inhibitor
of β-arrestin recruitment mediated by ETA compared to the ETB receptor. In the ETA vasoconstrictor assay,
ET-1, ET-2 and S6b were equipotent, full agonists and antagonists tested behaved in a competitive manner,
although afﬁnities were lower than predicted from the competition binding experiments in left ventricle.
Signiﬁcance: These data suggest that the pharmacology of ETA and ETB receptors linked to G-protein- and β-
arrestin mediated responses was different and bosentan appeared to show bias, preferentially blocking ETA
mediated β-arrestin recruitment.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The endothelin (ET) antagonists, bosentan (Dingemanse and van
Giersbergen, 2004) and ambrisentan (Cheng, 2008) are clinically used
in the treatment of pulmonary arterial hypertension. Bosentan report-
edly has similar afﬁnity for both of the endothelin receptor subtypes
(Clozel et al., 1994), ETA and ETB, whereas ambrisentan is an ETA selec-
tive compound (Vatter and Seifert, 2006) although the degree of ETA
selectivity reported in the literature varied depending on whether it
was determined using animal or human, cloned or native receptor
systems (Maguire and Davenport, 2012; Palmer, 2009; Vatter et al.,
2002). A third antagonist, sitaxentan (Wu et al., 1997), is much more
ETA selective than ambrisentan. The optimal receptor selectivity forUnit, Level 6 ACCI, Box 110
+44 1223 762579; fax: +44
guire).
Y-NC-ND license.treatment of PAH remains debatable (Davie et al., 2009) but an ETA se-
lective compound has the advantage of leaving unaffected potentially
beneﬁcial vasodilator (Takayanagi et al., 1991) and clearing ETB recep-
tors (Johnström et al., 2005; Kelland et al., 2010) that are present, for
example on endothelial cells (Bacon et al., 1996; Gardiner et al., 1994)
and expressed at particularly high densities in the lung and kidney
(Johnström et al., 2002, 2006).
Endothelin peptides mediate their cellular actions via interaction
with the two G protein-coupled receptors (GPCRs), ETA and ETB (Arai
et al., 1990; Sakurai et al., 1990). Agonist binding activates canonical
G-protein-linked intracellular signalling cascades with subsequent re-
ceptor phosphorylation leading to recruitment of the scaffolding pro-
tein β-arrestin which may result in receptor desensitisation and
internalisation (Dai and Galligan, 2006; Drake et al., 2006). It is now
known that GPCRs can couple promiscuously to multiple G protein
classes but may also activate signalling pathways such as the MAP ki-
nases in a G protein-independent manner via complexes of the receptor
with β-arrestin 1 or 2 (Schulte and Levy, 2007). Ligand-speciﬁc pathway
545J.J. Maguire et al. / Life Sciences 91 (2012) 544–549modulation (biased agonism/biased antagonism) may have important
therapeutic application (Whalen et al., 2011; Zheng et al., 2010), but lit-
tle is known about the potential for pathway bias of ET peptides and ET
receptor antagonists. Our aimwas to determine the ability of ET peptides
and related agonists to recruit β-arrestin via ETA and ETB receptors and to
compare the ability of well characterised ET receptor selective and non-
selective antagonists to block these responses. These datawere then com-
pared to the human cardiovascular pharmacology of theses agonists and
antagonists determined by radioligand binding in human left ventricle
that expresses both ET receptor subtypes (Molenaar et al., 1993) and in
functional experiments in saphenous vein in which vasoconstriction is
mediated via the ETA receptor (Maguire and Davenport, 1995).
Materials and methods
Human tissue
Anonymised human cardiovascular tissue samples were used in
this study with local ethical approval (REC 05/Q0104/142). The sam-
ples were obtained from Papworth Hospital Research Tissue Bank
(Cambridgeshire 1 Research Ethics Committee reference 08/H0304/
56, samples collected with written informed patient consent). Unless
otherwise stated n-values refer to the number of patients from whom
tissue was obtained.
Competition binding assays in human left ventricle
Competition binding experiments were carried out as previously
described (Davenport and Kuc, 2005). Brieﬂy, sections of human
heart (10 μm) were pre-incubated in HEPES buffer and then with
[125I]ET-1 (0.1 nM) for 2 h at room temperature in the presence of in-
creasing concentrations of antagonists (1 pM to 100 μM). Non-speciﬁc
binding was determined in the presence of 1 μM of unlabelled ET-1.
Afﬁnities (KD) of antagonists for ETA and ETB receptors were deter-
mined using the non-linear curve ﬁtting programme KELL (Biosoft,
http://Biosoft.com).
β-Arrestin recruitment assay
Initial saturation binding experiments were performed, as previ-
ously described (Davenport and Kuc, 2005), tomeasure level of recep-
tor density in the CHO-K1 cells expressing either ETA or ETB receptors.
Brieﬂy, frozen cells were thawed and plated as per the manufacturer's
instructions. Cells were re-suspended in HEPES buffer and incubated
for 90 minutes with increasing concentrations of [125I]ET-1 (8 pM–
4 nM) at room temperature, non-speciﬁc binding was determined
using 1 μM ET-1. Binding equilibrium was broken by centrifugation
(20,000 ×g for 10 min), pellets were washed in Tris–HCl buffer (pH 7.4
at 4 °C), re-centrifuged and pellets counted using a gamma counter.
Protein determination carried out using BioRad DC assay. Data were
analysed, using the non-linear curve ﬁtting programme KELL (Biosoft,
http://Biosoft.com), to determine receptor afﬁnity (KD) and receptor
density in fmol mg−1 protein (BMAX).
Experiments were carried out using the DiscoveRx PathHunter®
eXpress β-Arrestin GPCR Assays (EDNRA and EDNRB) according to
the manufacturer's instructions. Brieﬂy, CHO-K1 cells expressing
either human ETA or human ETB were incubated with antagonists or
vehicle for 60 min at 37 °C. Increasing concentrations of ET and related
peptides were added and cells incubated for further 90 min at 37 °C.
Detection reagent solution was added and cells incubated for 2 hr
at room temperature. The resulting chemiluminescent signal was
measured and agonist concentration–response curves (CRC) in the
absence and presence of antagonists, measured as relative light
units, were normalised to the maximum response obtained to ET-1
in the same experiment. Resulting agonist CRC data were ﬁtted to a
4 parameter logistic equation using the curve ﬁtting program FigSys(Biosoft UK). Values of EC50 and EMAX were determined for agonists
and compared to control responses to ET-1. In the ETA and, to a lesser
extent, ETB assays all antagonists produced a concentration dependent
reduction in the maximum response of the agonist concentration–
response curves and therefore afﬁnities for the receptors were deter-
mined using the method described by Kenakin (1993).
Human saphenous vein vasoconstriction functional assay
Experiments were carried out as previously described (Maguire,
2002; Maguire et al., 1995). Brieﬂy, 4 mm rings of endothelium-
denuded human saphenous vein were set up for isometric force record-
ings. Cumulative CRCs were constructed to ET and related peptides
(10−10 to 10−6 M), once the maximum response to each agonist had
been achieved the curve was terminated by the addition of 100 mM
KCl to determine the maximal possible contractile response for each
preparation. In additional experiments, ET-1 CRCs were repeated in
the absence and presence of bosentan (0.3 μM–30 μM), ambrisentan
(30 nM–3 μM) or sitaxentan (30 nM–3 μM). Vein preparations were
incubated with antagonists for 40 minutes prior to addition of ET-1.
Agonist data were expressed as a % of the terminal KCl response and
were analysed using the non-linear iterative curve-ﬁtting programme
FigSys (Biosoft) to give values of pD2 (− log10 of the agonist concentra-
tion producing 50% of the maximum response) and EMAX(maximum
response to an agonist expressed as a %KCl). Antagonist afﬁnities (KB)
were determined by Schild analysis (Arunlakshana and Schild, 1959).
If not signiﬁcantly different from one, Schild slopes were constrained
to one to determine value of KB.
Materials
ET-1, ET-2, ET-3, sarafotoxin 6b (S6b) and sarafotoxin 6c (S6c)
were from The Peptide Institute (Osaka, Japan). BQ123 (cyclo[D-Asp-
L-Pro-D-Val-L-Leu-D-Trp-]) was from Novabiochem, BQ788 (N-cis-
2,6- dimethylpiperidinocarbonyl-γL-MeLeu-D-Trp(CooMe)-D-Nle-ONa)
fromNeosystems. Bosentanwas from Parke-Davis, sitaxentan fromPﬁzer
Inc., and ambrisentan from Gilead Sciences Inc. [125I]-ET-1 (2200 Ci/
mmol) was from PerkinElmer NEN® Radiochemicals.
Results
Afﬁnity and selectivity of endothelin receptor antagonists determined in
human left ventricle
BQ123 (ETA KD 0.73±0.22 nM, ETB KD 24.3±2.0 μM, ETA:ETB se-
lectivity 33288) ambrisentan (ETA KD 0.28±0.23 nM, ETB KD 0.25±
0.05 μM, ETA:ETB selectivity 893) and sitaxentan (ETA KD 1.65±
0.80 nM, ETB KD 327±134 μM, ETA:ETB selectivity 198,182) were con-
ﬁrmed as ETA selective antagonists with subnanomolar afﬁnities for
this subtype in human left ventricle. This compares to our previously
published data showing that bosentan does not distinguish between
human ETA and ETB receptors (one site ﬁt 77.6±7.9 nM, non-selective
(Peter and Davenport, 1996) and that BQ788 is highly ETB selective
(ETA KD 1.01±0.2 μM, ETB KD 9.81±1.32 nM, ETA:ETB selectivity 0.01)
(Russell and Davenport, 1996) in this tissue.
ETA mediated β-arrestin recruitment
Receptor density (BMAX) for ETA CHO-K1 cells was 30.4±4.4 fmol
mg−1 protein (n=3)with afﬁnity for [125I]ET-1 ofKD=0.24±0.05 nM.
In the absence of agonists, BQ123 (0.3–10 μM), ambrisentan (0.3–
30 μM) and sitaxsentan (0.01–10 μM) had no effect on basal activity
in this assay. Bosentan had no effect at 3 and 30 μM, but produced a
small increase in response (b10% of the maximum response to ET-1)
at 300 μM.
Table 1
Potency and efﬁcacy of endothelins and related peptides in the ETA and ETB β-arrestin
recruitment assays.
ETA ETB
pD2 EMAX (% ET-1) n pD2 EMAX (% ET-1) n
ET-1 9.38±0.09 100±2 11 9.04±0.10 100±2 12
ET-2 8.75±0.05⁎ 87±3⁎ 3 8.55±0.03⁎ 105±2 3
ET-3 7.31±0.05⁎ 31±1⁎ 6 9.44±0.09 83±4 3
S6b 8.83±0.03⁎ 45±2⁎ 9 9.11±0.08 99±5 7
S6c No response – 3 9.10±0.04 96±5 3
BQ3020 No response – 3 8.94±0.11 82±7 3
Values are mean±s.e. mean. n=Number of replicates. *Signiﬁcantly different from
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with S6c and ET-1(1–31) inactive (Fig. 1A). Interestingly, ET-2 and par-
ticularly ET-3 and S6b elicited maximum responses that were signiﬁ-
cantly less than that of ET-1 (Fig. 1A, Table 1). Responses to all
agonists were antagonised by BQ123 (0.3 μM–1 μM) in an apparently
non-competitive manner, with a BQ123 concentration-dependent re-
duction in maximum agonist response (Fig. 2). However, BQ123
appeared to produce agonist dependent afﬁnities that ranged from
0.3 nM to 30 nM, being least effective as an antagonist of ET-2 in this
assay (Table 2). All three non-peptide antagonists tested, bosentan,
ambrisentan and sitaxentan (Fig. 3 (A–C), produced rightward shifts
if the ET-1 curve with concentration-dependent decreases in maxi-
mum response resulting in afﬁnity estimates for the antagonism of
ET-1 in the low nanomolar range (Table 3).
ETB mediated β-arrestin recruitment
Receptor density (BMAX) for ETB CHO-K1 cells was 156.6±33.8 fmol
mg−1 protein (n=3)with afﬁnity for [125I]ET-1 ofKD=0.37±0.12 nM.
In the absence of agonists, BQ788 (0.1–100 μM), ambrisentan (0.1–
300 μM) and bosentan (0.1–300 μM) had no effect on basal activity in
this assay.
Agonist order of potency in the ETB assaywas ET-1=ET-3=S6b=
S6c=BQ3020>ET-2 (Fig. 1B). In contrast to the ETA assay maximum
responses to all agonists were more than 80% of the maximum re-
sponse to ET-1 (Table 1). BQ788 (1 μM) produced a reduction in max-
imum response to all agonists tested (Fig. 3F) and therefore afﬁnity
was determined as for the ETA assay. The afﬁnity for BQ788 was com-
parable for all agonists tested of between 0.5 nM and 2 nM (Table 2).
The afﬁnities of bosentan and ambrisentan to block ET-1 mediated
β-arrestin recruitment in the ETB assay were two orders of magnitude
less than for BQ788 with both antagonists exhibiting ETA selectivity
for β-arrestin recruitment (Table 3, Fig. 3D and E).
Human saphenous vein vasoconstriction functional assay
ET-1, ET-2 and S6b were equipotent constrictors of human saphe-
nous veins with comparable maximum responses (ET-1 pD2 8.57±
0.06, EMAX 84±2, n=98; ET-2 pD2 8.15±0.20, EMAX 85±5, n=8;
S6b pD2 8.09±0.09, EMAX 89±2, n=9). ET-3 was much less potent
than these with the concentration–response curve incomplete at
1 μM. S6c (n=9) and BQ3020 (n=6) were essentially inactive over
the concentration range tested. BQ123, bosentan, ambrisentan and
sitaxsentan produced concentration-dependent, parallel rightward
shifts of the ET-1 CRC without affecting maximum response. Schild
analysis conﬁrmed that antagonism at the concentrations tested
appeared competitive, as Schild slopeswere close to unity. Afﬁnities de-
termined in the functional assay were lower than predicted from the
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Fig. 1. Concentration–response curves to endothelin, sarafotoxin and related peptides
in the (A) ETA and (B) ETB β-arrestin recruitment assays.for the non-peptide antagonist ambrisentanwhich had a KB determined
for antagonism of ET-1 mediated vasoconstriction 800 fold lower than
the afﬁnity determined in the competition experiment (Table 4).
Discussion
In human blood vessels, from a range of vascular beds, the ETA
receptor predominates on medial smooth muscle cells and mediates
vasoconstriction (Lipa et al., 1999; Maguire and Davenport, 1995;
Nilsson et al., 1997; Spieker et al., 2003). In the ETA mediated recruit-
ment of β-arrestin assay we have found that the order of potency of
endogenous endothelins and related sarafotoxins is as previously
obtained for constriction of human isolated blood vessels, such as sa-
phenous vein (Maguire and Davenport, 1995). One striking difference
between these two assays was the observation that in the β-arrestin
assay compared to ET-1 other agonists, particularly ET-3 and S6b,
appeared to be partial agonists. However, we have previously reported
that in saphenous vein, although maximum vasoconstrictor responses





























 +   1µM BQ123
D
-Log10 [S6b] M-Log10 [ET-3] M
 +0.3µM BQ123
Fig. 2. Antagonism of (A) ET-1, (B) ET-2, (C) ET-3 and (D) S6b mediated β-arrestin
recruitment via the ETA receptor by 0.3 μM (■) and 1 μM (▲) BQ123.
Table 2
Afﬁnity (KB) estimates of subtype selective peptide antagonists BQ123 and BQ788
determined in ETA and ETB β-arrestin recruitment assays, respectively.
ETA Assay BQ123 (KB) n ETB Assay BQ788 (KB) n
ET-1 8.36 nM 6 2.11 nM 3
ET-2 32.8 nM 3 1.33 nM 3
ET-3 1.05 nM 3 1.49 nM 3
S6b 1.35 nM 6 0.66 nM 3
S6c ND 0.76 nM 3
BQ3020 ND 0.51 nM 3
n=number of replicates. ND=not determined.
Table 3
Afﬁnity of non-peptide endothelin antagonists determined against ET-1 in ETA and ETB
β-arrestin recruitment assays.
ETA Assay (pKB) n ETB Assay (pKB) n ETA:ETB selectivity
Bosentan 8.01±0.02 8 6.15±0.01 6 73
Ambrisentan 8.73±0.08 8 5.90±0.23 9 677
Sitaxsentan 8.38±0.07 9 ND –
n=number of replicates. ND=not determined.
547J.J. Maguire et al. / Life Sciences 91 (2012) 544–549could be obtained on a maximal response to S6b but no additional
response to S6b could be achieved in the presence of a maximal re-
sponse to ET-1 (Maguire et al., 1996). In the same study, in cross-
desensitisation experiments, S6b had no effect in veins rendered insen-
sitive to ET-1 by repeated administration whereas veins insensitive to
S6b responded to ET-1. One explanation for these observations is that
S6b is a partial agonist at the ETA receptor but that this ismore apparent
in the β-arrestin assay because this assay provides a direct measure of
β-arrestin binding to the receptor (one to one stoichiometry) compared
to the more ampliﬁed vasoconstrictor assay. In the ETB β-arrestin re-
cruitment assay the order of potency of the endothelins and related
peptides was as expected for this subtype (Sakurai et al., 1990) and, in
contrast to the ETA assay, all peptides tested appeared to be full agonists.
We carried out saturation binding assays in both the ETA and ETB
expressing CHO-K1 cells and conﬁrmed that receptor densities in both
cell lines was in the same range as expressed in native human tissues,
for example human heart (91.7±3.2 fmol mg−1 protein, (Peter and
Davenport, 1996)) and coronary artery (20.6±2.1 fmol mg−1 protein
(Bacon et al., 1996)).
Recruitment of β-arrestin, following agonist binding to a GPCR, re-
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Fig. 3. Concentration-dependent inhibition of ET-1 responses in the ETA mediated β-arresti
β-arrestin assay by (D) bosentan, (E) ambrisentan and (F) BQ788.(desensitisation) and may target the receptor for subsequent internali-
sation and trafﬁcking (see Fergusson 2001). It has been shown that, fol-
lowing agonist activation, the ETB receptor is rapidly desensitised by
phosphorylation (Cramer et al., 1998), internalised (Wu-Wong et al.,
1995) and targeted to the late endosomal/lysosomal pathway for degra-
dation (Bremnes et al., 2000; Oksche et al., 2000), a mechanism that
effectively removes endothelin peptides, for example, from the plasma.
Efﬁcacious recruitment of β-arrestin by agonists activating the ETB
receptor, as observed in this study, is therefore consistent with the hy-
pothesis that this subtype acts as a clearing receptor (Johnström et al.,
2005; Kelland et al., 2010). We found that ET-1 was equally potent in
the ETA-mediated β-arrestin recruitment ass ay as the ETB. However,
whilst the ETA subtype is also internalised following activation, this
occurs more slowly than for the ETB receptor (Cramer et al., 1998) and
it has been demonstrated that ET-1 remains associated with the recep-
tor for up to 60 minutes after internalisation (Wang et al., 2000). This
has beenproposed to explain in part the long-lasting vascular responses
to ET-1 mediated by the ETA receptor.
In the endothelin ﬁeld there are many reports of agonist-speciﬁc
effects of ETA receptor antagonists. For example, we and others have
previously demonstrated that BQ123 is a more potent inhibitor of S6b-
mediated vascular responses than ET-1 (Bodelsson and Stjernquist,
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n assay by (A) bosentan, (B) ambrisentan and (C) sitaxentan and in the ETB-mediated
Table 4
Antagonist afﬁnities, ETA KB, determined against ET-1 mediated vasoconstriction in
human saphenous vein by Schild analysis compared to ETA KD obtained in competition
binding experiments using human left ventricle.
KB⁎ n KD n KB/KD
Bosentan 1.59 μM 4 77.6±7.9 nM 3 21
Ambrisentan 220 nM 6 0.28±0.23 nM 4 785
Sitaxsentan 64.6 nM 8 1.65±0.80 nM 4 39
BQ123 141.3 nM 8 0.73±0.22 nM 3 194
*Slopes of Schild regressions not signiﬁcantly different from one. Therefore, KB values
were calculated from Schild regressions with slopes constrained to unity.
548 J.J. Maguire et al. / Life Sciences 91 (2012) 544–549study provide evidence that the afﬁnity of BQ123 as an antagonist
of ETA-mediated β-arrestin recruitment was agonist-dependent, con-
sistent with an allosteric mode of action of this compound [44]
(Sokolowsky, 1993) whereas in the ETB assay BQ788 did not distinguish
between the different agonists. Whether non-peptide antagonists also
show characteristics consistent with allosteric modulation of endothelin
receptor function requires further investigation. The possibility that ETA
antagonists may act as allosteric modulators at this receptor has been
discussed in a recent review (De Mey et al., 2011). Of particular interest
was our observation that BQ123 was least effective in antagonising
the response to ET-2. There is emerging evidence that ET-2 may have
distinct physiological/pathophysiological roles to ET-1 (Ling et al., in
press) for example in ovulation (Al-Alem et al., 2007; Bridges et al.,
2010) and cancer (Grimshaw et al., 2002; Tanese et al., 2010). It may
therefore be important to determine to what extent endothelin antago-
nists designed for clinical use are effective blockers of both ET-1 and
ET-2 function. In the ETA β-arrestin assay we observed that similar to
BQ123, the non-peptide antagonists, ambrisentan, sitaxsentan and
bosentan, produced rightward shifts of the concentration–response
curves to ET-1 with an antagonists concentration-dependent reduction
in ET-1 maximum response, consistent with a non-competitive mode
of action. This contrasted with the apparent competitive actions of
these antagonists determined against ET-1 contraction in human isolat-
ed saphenous vein. A possible explanation is that hemi-equilibrium con-
ditions are achieved in the β-arrestin assay. The reduction in maximum
agonist response in the presence of increasing concentrations of antago-
nist was less pronounced in the ETB assay and this may result from the
higher density of receptors in this assay compared to the ETA assay
resulting in greater ETB receptor reserve and preservation of maximum
response over a wider antagonist concentration range.
The established ETA selectivity of ambrisentan and sitaxentan was
conﬁrmed in the human ETA and ETB β-arrestin assays however,
bosentan, which does not distinguish between the two receptor sub-
types expressed in human heart, was an ETA selective antagonist in
the β-arrestin assay with an afﬁnity comparable to that predicted by
the human heart binding data. It is now recognised that in addition
to a role in GPCR desensitisation and internalisation, β-arrestin may
also activate GPCR-mediated signalling pathways such as the MAP
kinase cascade (Daake et al., 1998; Ferguson, 2001). ET-1 has been
shown to stimulate pulmonary, but not aortic, smooth muscle cell
migration by activating ERK1/2 MAP kinase (Meoli and White, 2010)
and this effect of ET-1 may be ampliﬁed by the bone morphogenetic
system (Yamanaka et al., 2010) and contribute to the remodelling of
pulmonary arteries that occurs in pulmonary arterial hypertension.
Our data suggest that bosentan exhibits ETA bias for β-arrestin recruit-
ment. Whether preferential blockade of ETA mediated β-arrestin-
stimulated ERK1/2/ signalling contributes to the clinical beneﬁt of
bosentan in patients with PAH remains to be investigated.
Conclusion
The relative potency of endothelin and related peptide in the ETA
and ETB mediated β-arrestin recruitment assays described in this
study was as expected for the two receptor subtypes. However, thisstudy revealed that at the ETA receptor, compared to ET-1 all other
agonists tested were partial agonists. Differences in the predicted
pharmacology of antagonists were also revealed in the β-arrestin
assays. Speciﬁcally, the peptide antagonist BQ123 behaved as an allo-
steric modulator of agonist activity in the ETA assay, exhibiting
agonist-dependent afﬁnities. The non-peptide compound bosentan
was a potent ETA-selective antagonist in the β-arrestin assays in con-
trast to its non-selective proﬁle determined in competition binding
assays in human heart that possesses both ETA and ETB receptors.
The signiﬁcance of these data requires further understanding of the
potential contribution of β-arrestin mediated signalling to endothelin
receptor function in diseases such as pulmonary arterial hypertension.
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